Implication of JNK pathway on tau pathology and cognitive decline in a senescence-accelerated mouse model

Experimental Gerontology

Volumn 48, Issue 6, 2013, Pages 565-571

  Orejana, Lourdes ^a   Barros Miñones, Lucía ^a   Aguirre, Norberto ^a   Puerta, Elena ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Alzheimer's disease; C Jun N terminal kinase (JNK); D JNKI 1; Protein phosphatase 2A (PP2A); SAMP8; Sildenafil; Tau

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE 2A; SILDENAFIL; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; MAZE TEST; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPATIAL LEARNING; SPATIAL MEMORY; TAUOPATHY;

AGING; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MAP KINASE SIGNALING SYSTEM; MAZE LEARNING; MICE; PHOSPHORYLATION; PIPERAZINES; PURINES; SPACE PERCEPTION; SULFONES; TAU PROTEINS; TAUOPATHIES; VASODILATOR AGENTS;

ANIMALIA; MUS;

EID: 84876434217     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.03.001     Document Type: Article

References (60)

1. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
2. Ashe K.H. A tale about tau. N. Engl. J. Med. 2007, 357:933-935.
3. Ashe K.H., Zahs K.R. Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
4. Bancher C., Braak H., Fischer P., Jellinger K.A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett. 1993, 162:179-182.
5. Barr R.K., Kendrick T.S., Bogoyevitch M.A. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 2002, 277:10987-10997.
6. Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., Andorfer C., Rosenberry T.L., Lewis J., Hutton M., Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 2007, 27:3650-3662.
7. Bogoyevitch M.A., Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol. Mol. Biol. Rev. 2006, 70:1061-1095.
8. Bonny C., Oberson A., Negri S., Sauser C., Schorderet D.F. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001, 50:77-82.
9. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., Bogousslavsky J., Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003, 9:1180-1186.
10. Buee-Scherrer V., Goedert M. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett. 2002, 515:151-154.
11. Butterfield D.A., Poon H.F. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp. Gerontol. 2005, 40:774-783.
12. Canudas A.M., Gutierrez-Cuesta J., Rodriguez M.I., Acuna-Castroviejo D., Sureda F.X., Camins A., Pallas M. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech. Ageing Dev. 2005, 126:1300-1304.
13. Cheng H., Yu J., Jiang Z., Zhang X., Liu C., Peng Y., Chen F., Qu Y., Jia Y., Tian Q., Xiao C., Chu Q., Nie K., Kan B., Hu X., Han J. Acupuncture improves cognitive deficits and regulates the brain cell proliferation of SAMP8 mice. Neurosci. Lett. 2008, 432:111-116.
14. Del Valle J., Duran-Vilaregut J., Manich G., Casadesus G., Smith M.A., Camins A., Pallas M., Pelegri C., Vilaplana J. Early amyloid accumulation in the hippocampus of SAMP8 mice. J. Alzheimers Dis. 2010, 19:1303-1315.
15. Delacourte A. The natural and molecular history of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:187-194.
16. Gong C.X., Singh T.J., Grundke-Iqbal I., Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 1993, 61:921-927.
17. Gong C.X., Shaikh S., Wang J.Z., Zaidi T., Grundke-Iqbal I., Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 1995, 65:732-738.
18. Goni-Allo B., Puerta E., Ramos M., Lasheras B., Jordan J., Aguirre N. Minoxidil prevents 3,4-methylenedioxymethamphetamine-induced serotonin depletions: role of mitochondrial ATP-sensitive potassium channels, Akt and ERK. J. Neurochem. 2008, 104:914-925.
19. Guadagna S., Esiri M.M., Williams R.J., Francis P.T. Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia. Neurobiol. Aging 2012, 33:2798-2806.
20. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 2003, 60:729-736.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
22. Iqbal K., Liu F., Gong C.X., Alonso Adel C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009, 118:53-69.
23. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T., Imahori K. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 1993, 325:167-172.
24. Kim B.J., Ryu S.W., Song B.J. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J. Biol. Chem. 2006, 281:21256-21265.
25. Kimura T., Ono T., Takamatsu J., Yamamoto H., Ikegami K., Kondo A., Hasegawa M., Ihara Y., Miyamoto E., Miyakawa T. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 1996, 7:177-181.
26. Kobayashi S., Ishiguro K., Omori A., Takamatsu M., Arioka M., Imahori K., Uchida T. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett. 1993, 335:171-175.
27. Kosik K.S. Tau protein and Alzheimer's disease. Curr. Opin. Cell Biol. 1990, 2:101-104.
28. Kumar V.B., Franko M.W., Farr S.A., Armbrecht H.J., Morley J.E. Identification of age-dependent changes in expression of senescence-accelerated mouse (SAMP8) hippocampal proteins by expression array analysis. Biochem. Biophys. Res. Commun. 2000, 272:657-661.
29. Lauckner J., Frey P., Geula C. Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles. Neurobiol. Aging 2003, 24:767-776.
30. Lee V.M., Trojanowski J.Q. Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease. Neurology 2001, 56:S26-S30.
31. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22:1942-1950.
32. Liu R., Zhou X.W., Tanila H., Bjorkdahl C., Wang J.Z., Guan Z.Z., Cao Y., Gustafsson J.A., Winblad B., Pei J.J. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J. Cell. Mol. Med. 2008, 12:241-257.
33. Liu W., Liu C., Zhu J., Shu P., Yin B., Gong Y., Qiang B., Yuan J., Peng X. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiol. Aging 2012, 33:522-534.
34. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., Hanger D., Mulot S., Marquardt B., Stabel S., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 1994, 4:1077-1086.
35. Luna-Munoz J., Chavez-Macias L., Garcia-Sierra F., Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 2007, 12:365-375.
36. Maccioni R.B., Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol. Rev. 1995, 75:835-864.
37. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van Lint J., Vandenheede J.R., Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 1992, 314:315-321.
38. Maurage C.A., Sergeant N., Ruchoux M.M., Hauw J.J., Delacourte A. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol. 2003, 105:89-97.
39. Mohit A.A., Martin J.H., Miller C.A. p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 1995, 14:67-78.
40. Orejana L., Barros-Minones L., Jordan J., Puerta E., Aguirre N. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol. Aging 2012, 33(625):e611-e620.
41. Pallas M., Camins A., Smith M.A., Perry G., Lee H.G., Casadesus G. From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J. Alzheimers Dis. 2008, 15:615-624.
42. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 1999, 58:1010-1019.
43. Ploia C., Antoniou X., Sclip A., Grande V., Cardinetti D., Colombo A., Canu N., Benussi L., Ghidoni R., Forloni G., Borsello T. JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. J. Alzheimers Dis. 2011, 26:315-329.
44. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
45. Reynolds C.H., Nebreda A.R., Gibb G.M., Utton M.A., Anderton B.H. Reactivating kinase/p38 phosphorylates tau protein in vitro. J. Neurochem. 1997, 69:191-198.
46. Ricobaraza A., Cuadrado-Tejedor M., Perez-Mediavilla A., Frechilla D., Del Rio J., Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
47. Sato S., Tatebayashi Y., Akagi T., Chui D.H., Murayama M., Miyasaka T., Planel E., Tanemura K., Sun X., Hashikawa T., Yoshioka K., Ishiguro K., Takashima A. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem. 2002, 277:42060-42065.
48. Shoji M., Iwakami N., Takeuchi S., Waragai M., Suzuki M., Kanazawa I., Lippa C.F., Ono S., Okazawa H. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res. Mol. Brain Res. 2000, 85:221-233.
49. Su J.H., Cummings B.J., Cotman C.W. Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites. Neuroreport 1994, 5:2358-2362.
50. Sun L., Liu S.Y., Zhou X.W., Wang X.C., Liu R., Wang Q., Wang J.Z. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 2003, 118:1175-1182.
51. Tajes M., Gutierrez-Cuesta J., Folch J., Ferrer I., Caballero B., Smith M.A., Casadesus G., Camins A., Pallas M. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J. Neuropathol. Exp. Neurol. 2008, 67:612-623.
52. Tajes M., Gutierrez-Cuesta J., Folch J., Ortuno-Sahagun D., Verdaguer E., Jimenez A., Junyent F., Lau A., Camins A., Pallas M. Neuroprotective role of intermittent fasting in senescence-accelerated mice P8 (SAMP8). Exp. Gerontol. 2010, 45:702-710.
53. Tomobe K., Nomura Y. Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence. Neurochem. Res. 2009, 34:660-669.
54. Tran H.T., Sanchez L., Brody D.L. Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice. J. Neuropathol. Exp. Neurol. 2012, 71:116-129.
55. Wang J.Z., Gong C.X., Zaidi T., Grundke-Iqbal I., Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J. Biol. Chem. 1995, 270:4854-4860.
56. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 2007, 19:142-149.
57. Yoshida H., Hastie C.J., McLauchlan H., Cohen P., Goedert M. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J. Neurochem. 2004, 90:352-358.
58. Zhao S., Zhang L., Lian G., Wang X., Zhang H., Yao X., Yang J., Wu C. Sildenafil attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-kappaB signaling pathways in N9 microglia. Int. Immunopharmacol. 2011, 11:468-474.
59. Zhu X., Castellani R.J., Takeda A., Nunomura A., Atwood C.S., Perry G., Smith M.A. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Dev. 2001, 123:39-46.
60. Zhu X., Raina A.K., Rottkamp C.A., Aliev G., Perry G., Boux H., Smith M.A. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 2001, 76:435-441.